Using biomaterials to boost T cell immunity against cancer
Official title: Biomaterials to Create T Cell Immunity
Funded at Harvard University · NIH-9870084 · Data updated 2026-11-12
This study is exploring new ways to boost the immune system's T cells, which help fight cancer, by using special materials to create artificial cells that can better activate them, with the hope of developing improved treatments for cancer patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 25, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2019 |
| Award (this year) | $8,192,428 |
| NIH project number | 1U54CA244726-01 |
| Project ID | NIH-9870084 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancer who may benefit from enhanced T cell responses.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have a functional immune system may not receive benefits from this research.
What this research studies
This research focuses on enhancing the immune response of T cells, which are crucial for fighting cancer, by utilizing innovative biomaterials. The approach involves creating artificial antigen-presenting cells that can effectively activate T cells, leading to a stronger anti-cancer response. By collaborating with experts in bioengineering and cancer immunology, the project aims to develop new therapies that can improve T cell function and increase their numbers. Patients may benefit from these advancements through more effective cancer immunotherapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors.
How similar studies have gone: Previous research has shown promise in using biomaterials for immunotherapy, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
Harvard University
Cambridge, United States Active
Researchers
- Principal investigator: Mooney, David J — Harvard University
- Study coordinator: Mooney, David J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how venom glands develop to reveal new medicines
A Corsortium at Harvard studies how venom glands form and work in different animals to uncover new ways to create and use powerful medicines for human health.
-
Muscle Mass: a Key Missing Piece in How We Model Movement
This project studies how adding muscle mass to computer models changes predictions of movement, aiming to improve mobility for people of all ages.
-
Synthetic circuit tools to precisely control human immune cells
Aims to design safe, programmable gene circuits that can steer human immune cells for better therapies.
-
HPF-X: A fast, buffer-exchanging high-pressure freezing tool for capturing rapid cellular events
A new tool called HPF-X will let scientists freeze cells at precise moments after stimulation, so we can see rapid molecular changes in neuroscience and related fields.
-
Pathways and factors to prevent early-onset colorectal tumors
This NIH grant would explore why colorectal cancer is rising in people under 50 and identify clues we can use to prevent it.
-
Define how DNA damage leads to unexplained cancer mutations
A research project is exploring how DNA damage from everyday biology and the environment creates cancer-related mutation patterns, to better understand cancer causes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.